BioSpace News Archive

Pharm Country

Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy

Renalytix (NASDAQ: RNLX) (LSE: RENX) announced the publication of positive study results for KidneyIntelX™ as a risk monitoring tool to assess impact and response to novel treatments for patients with diabetes and chronic kidney disease (CKD) at increased risk for cardiovascular events.

January 11, 2022
·
7 min read
Business

Curebase and Persephone Biosciences Partner in Clinical Trial of Colorectal Cancer Among Diverse Populations

Curebase and Persephone Biosciences today announced a collaboration for the long-term clinical study of patients with colorectal cancer (CRC).

January 11, 2022
·
4 min read
Biotech Bay

Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference

Biomea Fusion, Inc. announced it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference.

January 11, 2022
·
1 min read
Drug Development

Myrtelle Announces Successful Completion of Initial Stage of Phase 1/2 Clinical Trial of Proprietary Gene Therapy for Canavan Disease and Expands Treatment to Younger Patients

Myrtelle Inc today announced that it successfully administered gene therapy in its First-in-Human Phase 1/2 clinical trial of Canavan disease (CD), a fatal childhood genetic disorder characterized by the degeneration of the white matter in the brain.

January 11, 2022
·
4 min read
FDA

Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console

Avinger, Inc. today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console.

January 11, 2022
·
5 min read
Job Trends

AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025

AbbVie (NYSE: ABBV) is confirming prior revenue guidance of greater than $15 billion in combined Rinvoq (upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in 2025.

January 11, 2022
·
3 min read
ImmunoPrecise Antibodies Announces Grant of Stock Options - Jan 11, 2022

IMMUNOPRECISE ANTIBODIES LTD. announced that on January 7, 2022 its board of directors approved the grant of 170,000 stock options under its stock option plan to acquire up to an aggregate of 170,000 common shares in the capital of IPA.

January 11, 2022
·
1 min read
Genetown

T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA).

January 11, 2022
·
5 min read
Business

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021.

January 11, 2022
·
5 min read
Genetown

T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA).

January 11, 2022
·
4 min read